Summary
Gilead Sciences, Inc. (GILD) reported revenues of $6.60 billion for the third quarter of 2023, a 5% increase year-over-year, driven by growth in HIV and Oncology segments. However, net income attributable to Gilead saw a significant decrease of 9% to $1.045 billion, or $0.83 per diluted share. This decline was primarily influenced by a $525 million litigation accrual for settlements related to HIV antitrust litigation, coupled with higher operating costs and tax expenses. For the first six months of 2023, revenues grew 1% to $12.95 billion, while net income more than doubled to $2.06 billion, largely due to the absence of a significant $2.7 billion IPR&D impairment charge recognized in the prior year's comparable period. The company's strategic focus continues to be on advancing innovative medicines for life-threatening diseases. Acquisitions in the oncology space, such as XinThera and Tmunity, alongside collaborations like Arcellx, highlight Gilead's commitment to expanding its pipeline. Despite a challenging legal environment and increased R&D spending, Gilead's core HIV franchise remains robust, and its cell therapy and oncology products are demonstrating strong growth.
Financial Highlights
56 data points| Revenue | $6.60B |
| Cost of Revenue | $1.44B |
| Gross Profit | $5.16B |
| SG&A Expenses | $1.85B |
| Operating Expenses | $4.93B |
| Operating Income | $1.67B |
| Interest Expense | $230.00M |
| Net Income | $1.04B |
| EPS (Basic) | $0.84 |
| EPS (Diluted) | $0.83 |
| Shares Outstanding (Basic) | 1.25B |
| Shares Outstanding (Diluted) | 1.26B |
Key Highlights
- 1Total revenues increased by 5% to $6.6 billion in Q3 2023 compared to the prior year, with first half revenues up 1% to $13.0 billion.
- 2Net income attributable to Gilead decreased by 9% to $1.045 billion ($0.83 EPS) for Q3 2023, primarily due to a $525 million litigation accrual.
- 3For the first six months of 2023, net income attributable to Gilead increased significantly to $2.055 billion ($1.63 EPS), largely due to the absence of a $2.7 billion IPR&D impairment from the prior year.
- 4Product sales in the HIV segment increased by 9% and 11% for the three and six months ended June 30, 2023, respectively, driven by Biktarvy and Descovy.
- 5Oncology product sales, particularly Cell Therapy (Yescarta, Tecartus) and Trodelvy, showed strong growth, increasing by 27% and 63% respectively for the quarter.
- 6Veklury (COVID-19 treatment) sales declined significantly by 43% and 58% for the three and six months ended June 30, 2023, due to lower demand as COVID-19 hospitalizations decreased.
- 7Research and Development expenses increased by 28% and 25% for the three and six months ended June 30, 2023, reflecting investments in oncology clinical activities and acquisitions/collaborations.